Pharmaceutical Preparations · DE · CIK 1806952
Advancing next-generation CAR T-cell therapies for patients with cancer, aiming for long-lasting clinical responses
Comparable business profile · signals at a glance
In the 90 days to Mar 6, 2026: 2 insiders bought $25.0M · 4 sold $338K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 6, 2026 | Arch Venture Partners Ix Overage, L.P.TenPercentOwner | Buy | 488,090 | $25.61 | $12.5M |
| Mar 6, 2026 | Berns Paul LTenPercentOwner | Buy | 488,090 | $25.61 | $12.5M |
| Feb 11, 2026 | Seely LynnPresident and CEO | Sell | 7,455 | $23.39 | $174K |
| Feb 11, 2026 | Lee Gary K.Chief Scientific Officer | Sell | 1,671 | $23.39 | $39K |
| Feb 11, 2026 | Hill Stephen J.Chief Operating Officer | Sell | 1,236 | $23.39 | $29K |
| Feb 10, 2026 | Seely LynnPresident and CEO | Sell | 438 | $23.12 | $10K |
| Feb 10, 2026 | Bulis Veronica SanchezVP, Corporate Controller | Sell | 254 | $23.12 | $6K |
| Feb 10, 2026 | Lee Gary K.Chief Scientific Officer | Sell | 147 | $23.12 | $3K |
| Feb 10, 2026 | Hill Stephen J.Chief Operating Officer | Sell | 109 | $23.12 | $3K |
| Dec 30, 2025 | Bulis Veronica SanchezVP, Corporate Controller | Sell | 936 | $32.32 | $30K |
| Dec 24, 2025 | Bulis Veronica SanchezVP, Corporate Controller | Sell | 1,136 | $38.67 | $44K |
| Nov 10, 2025 | Seely LynnPresident and CEO | Sell | 412 | $16.11 | $7K |
| Nov 10, 2025 | Bulis Veronica SanchezVP, Corporate Controller | Sell | 239 | $16.10 | $4K |
| Nov 10, 2025 | Lee Gary K.Chief Scientific Officer | Sell | 138 | $16.16 | $2K |
| Nov 10, 2025 | Hill Stephen J.Chief Operating Officer | Sell | 95 | $16.12 | $2K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.